Diagnosis and treatment of myeloma bone disease

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Citations (Scopus)

Abstract

INTRODUCTION Multiple myeloma (MM) is the most common cancer to metastasize to bone, with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathological fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the past several years. These studies have helped to identify novel targets for treating myeloma bone disease and are discussed subsequently in this chapter. The clinical and economic impact of myeloma bone disease in patients with myeloma can be catastrophic. Saad and coworkers retrospectively evaluated data from patients on the control arms of randomized trials of zoledronic acid to assess the impact of pathological fractures on survival of patients with malignant disease. A total of 3049 patients with metastatic bone disease were included in this study, of which 513 had myeloma. Patients with myeloma had the highest incidence of fracture (43%) over the 21 months of the study compared to patients with breast cancer, prostate cancer, and lung cancer.

Original languageEnglish (US)
Title of host publicationTreatment of Multiple Myeloma and Related Disorders
PublisherCambridge University Press
Pages64-75
Number of pages12
ISBN (Print)9780511551901, 9780521515030
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Bone Diseases
Bone and Bones
Spontaneous Fractures
Therapeutics
zoledronic acid
Multiple Myeloma
Lung Neoplasms
Prostatic Neoplasms
Neoplasm Metastasis
Neoplasms
Bone Resorption
Tumor Burden
Osteoblasts
Osteogenesis
Economics
Breast Neoplasms
Survival
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roodman, G. D. (2008). Diagnosis and treatment of myeloma bone disease. In Treatment of Multiple Myeloma and Related Disorders (pp. 64-75). Cambridge University Press. https://doi.org/10.1017/CBO9780511551901.006

Diagnosis and treatment of myeloma bone disease. / Roodman, G. David.

Treatment of Multiple Myeloma and Related Disorders. Cambridge University Press, 2008. p. 64-75.

Research output: Chapter in Book/Report/Conference proceedingChapter

Roodman, GD 2008, Diagnosis and treatment of myeloma bone disease. in Treatment of Multiple Myeloma and Related Disorders. Cambridge University Press, pp. 64-75. https://doi.org/10.1017/CBO9780511551901.006
Roodman GD. Diagnosis and treatment of myeloma bone disease. In Treatment of Multiple Myeloma and Related Disorders. Cambridge University Press. 2008. p. 64-75 https://doi.org/10.1017/CBO9780511551901.006
Roodman, G. David. / Diagnosis and treatment of myeloma bone disease. Treatment of Multiple Myeloma and Related Disorders. Cambridge University Press, 2008. pp. 64-75
@inbook{f42d5cd806044593a77cef1e1ab91ccc,
title = "Diagnosis and treatment of myeloma bone disease",
abstract = "INTRODUCTION Multiple myeloma (MM) is the most common cancer to metastasize to bone, with up to 90{\%} of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60{\%} of patients develop pathological fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50{\%} in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the past several years. These studies have helped to identify novel targets for treating myeloma bone disease and are discussed subsequently in this chapter. The clinical and economic impact of myeloma bone disease in patients with myeloma can be catastrophic. Saad and coworkers retrospectively evaluated data from patients on the control arms of randomized trials of zoledronic acid to assess the impact of pathological fractures on survival of patients with malignant disease. A total of 3049 patients with metastatic bone disease were included in this study, of which 513 had myeloma. Patients with myeloma had the highest incidence of fracture (43{\%}) over the 21 months of the study compared to patients with breast cancer, prostate cancer, and lung cancer.",
author = "Roodman, {G. David}",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511551901.006",
language = "English (US)",
isbn = "9780511551901",
pages = "64--75",
booktitle = "Treatment of Multiple Myeloma and Related Disorders",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Diagnosis and treatment of myeloma bone disease

AU - Roodman, G. David

PY - 2008/1/1

Y1 - 2008/1/1

N2 - INTRODUCTION Multiple myeloma (MM) is the most common cancer to metastasize to bone, with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathological fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the past several years. These studies have helped to identify novel targets for treating myeloma bone disease and are discussed subsequently in this chapter. The clinical and economic impact of myeloma bone disease in patients with myeloma can be catastrophic. Saad and coworkers retrospectively evaluated data from patients on the control arms of randomized trials of zoledronic acid to assess the impact of pathological fractures on survival of patients with malignant disease. A total of 3049 patients with metastatic bone disease were included in this study, of which 513 had myeloma. Patients with myeloma had the highest incidence of fracture (43%) over the 21 months of the study compared to patients with breast cancer, prostate cancer, and lung cancer.

AB - INTRODUCTION Multiple myeloma (MM) is the most common cancer to metastasize to bone, with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathological fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the past several years. These studies have helped to identify novel targets for treating myeloma bone disease and are discussed subsequently in this chapter. The clinical and economic impact of myeloma bone disease in patients with myeloma can be catastrophic. Saad and coworkers retrospectively evaluated data from patients on the control arms of randomized trials of zoledronic acid to assess the impact of pathological fractures on survival of patients with malignant disease. A total of 3049 patients with metastatic bone disease were included in this study, of which 513 had myeloma. Patients with myeloma had the highest incidence of fracture (43%) over the 21 months of the study compared to patients with breast cancer, prostate cancer, and lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84882336908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882336908&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511551901.006

DO - 10.1017/CBO9780511551901.006

M3 - Chapter

AN - SCOPUS:84882336908

SN - 9780511551901

SN - 9780521515030

SP - 64

EP - 75

BT - Treatment of Multiple Myeloma and Related Disorders

PB - Cambridge University Press

ER -